Optical coherence tomography in myelin-oligodendrocyte-glycoprotein antibody-seropositive patients: a longitudinal study
暂无分享,去创建一个
F. Paul | R. Hohlfeld | E. Meinl | A. Blaschek | J. Bellmann-Strobl | A. Brandt | K. Ruprecht | M. Reindl | S. Jarius | N. Borisow | J. Havla | O. Outteryck | B. Knier | T. Kümpfel | H. Zimmermann | F. C. Oertel
[1] F. Paul,et al. Spinal cord lesions and atrophy in NMOSD with AQP4-IgG and MOG-IgG associated autoimmunity , 2018, Multiple sclerosis.
[2] F. Paul,et al. Diagnosis and Treatment of NMO Spectrum Disorder and MOG-Encephalomyelitis , 2018, Front. Neurol..
[3] F. Paul,et al. MOG antibody disease: A review of MOG antibody seropositive neuromyelitis optica spectrum disorder. , 2018, Multiple sclerosis and related disorders.
[4] G. Krishnamoorthy,et al. Pathogenicity of human antibodies against myelin oligodendrocyte glycoprotein , 2018, Annals of neurology.
[5] F. Paul,et al. Retinal ganglion cell loss in neuromyelitis optica: a longitudinal study , 2018, Journal of Neurology, Neurosurgery, and Psychiatry.
[6] P. Lebranchu,et al. Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults , 2018, Neurology.
[7] Jacqueline Palace,et al. MOG encephalomyelitis: international recommendations on diagnosis and antibody testing , 2018, Journal of Neuroinflammation.
[8] B. Weinshenker,et al. Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Autoantibody Status Predict Outcome of Recurrent Optic Neuritis. , 2018, Ophthalmology.
[9] K. Fujihara,et al. MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder , 2018, Front. Neurol..
[10] F. Paul,et al. Multicenter reliability of semiautomatic retinal layer segmentation using OCT , 2018, Neurology: Neuroimmunology & Neuroinflammation.
[11] Alexander U. Brandt,et al. Optical coherence tomography in neuromyelitis optica spectrum disorders: potential advantages for individualized monitoring of progression and therapy , 2017, EPMA Journal.
[12] C. Ahn,et al. Two case reports , 2017, Medicine.
[13] I. Nakashima,et al. Reversible paraspinal muscle hyperintensity in anti-MOG antibody–associated transverse myelitis , 2017, Neurology: Neuroimmunology & Neuroinflammation.
[14] M. Bradl,et al. Myelin Oligodendrocyte Glycoprotein: Deciphering a Target in Inflammatory Demyelinating Diseases , 2017, Front. Immunol..
[15] H. Heinze,et al. ADEM-like presentation, anti-MOG antibodies, and MS pathology: TWO case reports , 2017, Neurology: Neuroimmunology & Neuroinflammation.
[16] F. Paul,et al. Microstructural visual system changes in AQP4-antibody–seropositive NMOSD , 2017, Neurology: Neuroimmunology & Neuroinflammation.
[17] K. Fujihara,et al. MOG antibody–positive, benign, unilateral, cerebral cortical encephalitis with epilepsy , 2017, Neurology: Neuroimmunology & Neuroinflammation.
[18] F. Paul,et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: Afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients , 2016, Journal of Neuroinflammation.
[19] A. Verkman,et al. Complement-independent retinal pathology produced by intravitreal injection of neuromyelitis optica immunoglobulin G , 2016, Journal of Neuroinflammation.
[20] F. Paul,et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome , 2016, Journal of Neuroinflammation.
[21] B. Ertl-Wagner,et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis , 2016, Neurology: Neuroimmunology & Neuroinflammation.
[22] Pablo Villoslada,et al. The APOSTEL recommendations for reporting quantitative optical coherence tomography studies , 2016, Neurology.
[23] B. Uitdehaag,et al. Timing of retinal neuronal and axonal loss in MS: a longitudinal OCT study , 2016, Journal of Neurology.
[24] T. Nakazawa,et al. Lesion length of optic neuritis impacts visual prognosis in neuromyelitis optica , 2016, Journal of Neuroimmunology.
[25] V. Fung,et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis , 2016, Multiple sclerosis.
[26] F. Paul,et al. Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case , 2016, Multiple sclerosis.
[27] R. Hohlfeld,et al. The search for the target antigens of multiple sclerosis, part 1: autoreactive CD4+ T lymphocytes as pathogenic effectors and therapeutic targets , 2016, The Lancet Neurology.
[28] H. Ishikawa,et al. Acute optic neuritis , 2015, Neurology: Neuroimmunology & Neuroinflammation.
[29] A. Traboulsee,et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders , 2015, Neurology.
[30] J. Benito-León,et al. Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease , 2015, Multiple sclerosis.
[31] Jacqueline Palace,et al. Neuromyelitis optica and multiple sclerosis: Seeing differences through optical coherence tomography , 2015, Multiple sclerosis.
[32] M. Motomura,et al. Antibodies to myelin oligodendrocyte glycoprotein in idiopathic optic neuritis , 2015, BMJ Open.
[33] T. Nakazawa,et al. MRI and retinal abnormalities in isolated optic neuritis with myelin oligodendrocyte glycoprotein and aquaporin-4 antibodies: a comparative study , 2015, Journal of Neurology, Neurosurgery & Psychiatry.
[34] G. Plant,et al. Quality control for retinal OCT in multiple sclerosis: validation of the OSCAR-IB criteria , 2015, Multiple sclerosis.
[35] S. Zamvil,et al. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? , 2015, Neurology: Neuroimmunology & Neuroinflammation.
[36] A. Straube,et al. Histopathology and clinical course of MOG-antibody-associated encephalomyelitis , 2015, Annals of clinical and translational neurology.
[37] V. Fung,et al. Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis , 2014, Journal of Neuroimmunology.
[38] F. Paul,et al. Dynamic formation of macular microcysts independent of vitreous traction changes , 2014, Neurology.
[39] K. Fujihara,et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders , 2014, Neurology.
[40] F. Paul,et al. Optic Neuritis Is Associated with Inner Nuclear Layer Thickening and Microcystic Macular Edema Independently of Multiple Sclerosis , 2013, PloS one.
[41] A. Lutterotti,et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders , 2011, Journal of Neuroinflammation.
[42] M. Duddy,et al. Seizures and Encephalitis in Myelin Oligodendrocyte Glycoprotein IgG Disease vs Aquaporin 4 IgG Disease , 2018, JAMA neurology.
[43] R. Hohlfeld,et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration , 2016, Journal of Neurology.
[44] Hilde van der Togt,et al. Publisher's Note , 2003, J. Netw. Comput. Appl..